WO2001072119A3 - Non-human animal model for growth deficiency and information processing or cognitive function defects and use thereof - Google Patents

Non-human animal model for growth deficiency and information processing or cognitive function defects and use thereof Download PDF

Info

Publication number
WO2001072119A3
WO2001072119A3 PCT/EP2001/003733 EP0103733W WO0172119A3 WO 2001072119 A3 WO2001072119 A3 WO 2001072119A3 EP 0103733 W EP0103733 W EP 0103733W WO 0172119 A3 WO0172119 A3 WO 0172119A3
Authority
WO
WIPO (PCT)
Prior art keywords
animal model
human animal
modified
cognitive function
growth
Prior art date
Application number
PCT/EP2001/003733
Other languages
French (fr)
Other versions
WO2001072119A2 (en
Inventor
Emmanuelle Cornali
Michael Christian Nehls
Volker Schlueter
Frank Wattler
Sigrid Wattler
Stefan Wolf
Original Assignee
Ingenium Pharmaceuticals Ag
Emmanuelle Cornali
Michael Christian Nehls
Volker Schlueter
Frank Wattler
Sigrid Wattler
Stefan Wolf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenium Pharmaceuticals Ag, Emmanuelle Cornali, Michael Christian Nehls, Volker Schlueter, Frank Wattler, Sigrid Wattler, Stefan Wolf filed Critical Ingenium Pharmaceuticals Ag
Priority to AU2001265855A priority Critical patent/AU2001265855A1/en
Publication of WO2001072119A2 publication Critical patent/WO2001072119A2/en
Publication of WO2001072119A3 publication Critical patent/WO2001072119A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a non-human animal model, particularly a mouse model, for growth deficiency and information procesing or cognitive function defects, in which modified growth hormone is expressed. The modified growth hormone and nucleic acids coding therefor are also provided, as are the correspondingly modified recombinant mouse and human growth hormones. The invention further provides uses for the non-human animal model and the modified growth hormones, in particular for the modified human growth hormone in treating medical conditions associated with over-expression of growth hormone or IGF-1.
PCT/EP2001/003733 2000-03-31 2001-04-02 Non-human animal model for growth deficiency and information processing or cognitive function defects and use thereof WO2001072119A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001265855A AU2001265855A1 (en) 2000-03-31 2001-04-02 Non-human animal model for growth deficiency and information processing or cognitive function defects and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10016083.2 2000-03-31
DE2000116083 DE10016083A1 (en) 2000-03-31 2000-03-31 Non-human animal model for growth deficiency and defects in information processing or cognitive function and its use

Publications (2)

Publication Number Publication Date
WO2001072119A2 WO2001072119A2 (en) 2001-10-04
WO2001072119A3 true WO2001072119A3 (en) 2002-02-07

Family

ID=7637142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/003733 WO2001072119A2 (en) 2000-03-31 2001-04-02 Non-human animal model for growth deficiency and information processing or cognitive function defects and use thereof

Country Status (3)

Country Link
AU (1) AU2001265855A1 (en)
DE (1) DE10016083A1 (en)
WO (1) WO2001072119A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020031829A1 (en) * 2000-08-15 2002-03-14 Brian Zambrowicz Arrayed collection of genomic clones
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
WO2020085788A1 (en) * 2018-10-24 2020-04-30 한국생명공학연구원 Dwarfism animal model having igf-1 genetic mutation and method for producing same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004788A1 (en) * 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
WO1999046298A2 (en) * 1998-03-12 1999-09-16 Universiteit Utrecht Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004788A1 (en) * 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
WO1999046298A2 (en) * 1998-03-12 1999-09-16 Universiteit Utrecht Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JIN L ET AL: "High resolution functional analysis of antibody-antigen interactions", J MOL BIOL, vol. 226, no. 3, 5 August 1992 (1992-08-05), pages 851 - 865, XP001030520 *
SMITH L ET AL: "Essential role of growth hormone in ischemia-induced retinal neovascularization", SCIENCE, vol. 276, no. 5319, 13 June 1997 (1997-06-13), pages 1706 - 1709, XP002179757 *
WICAR S ET AL: "Conformational changes in the reversed phase liquid chromatography of recombinant human growth hormone as a function of organic solvent: the molten globule state", ANAL CHEM, vol. 66, no. 22, 15 November 1994 (1994-11-15), pages 3908 - 3915, XP002179758 *

Also Published As

Publication number Publication date
WO2001072119A2 (en) 2001-10-04
DE10016083A1 (en) 2001-10-18
AU2001265855A1 (en) 2001-10-08

Similar Documents

Publication Publication Date Title
WO2003104270A3 (en) Dudulin genes, non-human animal model: uses in human hematological disease
WO2000018918A3 (en) Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
DE60033138D1 (en) POLYPEPTIDES WITH GALACTOSE OXIDASE ACTIVITY AND NUCLEIC ACIDS CODED THEREFOR
NZ509633A (en) A recombinant chimeric PEG-uricase with a long circulatory life and reduced immunogenicity
EP2036924A3 (en) Gene regulatory peptides
WO2000055318A3 (en) Abc1 polypeptide and methods and reagents for modulating cholesterol levels
WO2004007695A3 (en) Lactobacilli expressing biologically active polypeptides and uses thereof
HU9200548D0 (en) Improved activity process of recombined proteins
EP0681585A4 (en) Tata-binding protein associated factors, nucleic acids encoding tafs, and methods of use.
WO1997020933A3 (en) Mutational variants of mammalian ob gene proteins
WO2000069901A3 (en) Proteins with insulin-like activity useful in the treatment of diabetes
WO2001072119A3 (en) Non-human animal model for growth deficiency and information processing or cognitive function defects and use thereof
ZA200006309B (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof.
WO1999037782A3 (en) Frozen food product
DE10196565T1 (en) Recombinant human parathyroid hormone producing yeast transformant and method for producing the hormone
HK1047960A1 (en) polypeptide fragments comprising c-terminal portion of helicobacter catalase
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
EP0967276A3 (en) Anti-tumor agent comprising salmosin
EP0645454A3 (en) Chimeric somatostatin containing protein and coding DNA, immunogenic compositions and method for increasing farm animal productivity.
EP1050582A3 (en) Recombinant microorganisms expressing small rubber particle-associated protein
EP2055779A3 (en) Auxin transport proteins
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
EP1117419A4 (en) Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions
EP1362915A4 (en) Nomuraeae rileyi -origin ecdysteroid 22-oxidase and molt hormone inactivation system with the use of the same
DE69729780D1 (en) Protein with ethylenediamine-N, N'-dibarnsuccinic acid: ethylenediamine lyase activity and gene coding for it

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP